Akari Therapeutics (AKTX) EPS (Weighted Average and Diluted) (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly EPS (Weighted Average and Diluted) came in at -$0.0 in Q1 2026, down 79.34% year-on-year from -$0.0 in Q1 2025, and down 54.68% quarter-over-quarter from -$0.0 in Q4 2025.
Akari Therapeutics (AKTX) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.0 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.0, down 79.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.0 (up 24.58% YoY), and the FY2025 annual result was -$0.0, up 68.99% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.0 for Q1 2026 at Akari Therapeutics, down from -$0.0 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.0 in Q2 2025 to a low of -$0.0 in Q1 2023.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.0 (2024), against an average of -$0.0.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 86.45% in 2025 and slumped 79.34% in 2026, its largest moves.
- Akari Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.0 in 2023, then surged by 69.59% to -$0.0 in 2024, then surged by 50.17% to -$0.0 in 2025, then tumbled by 54.68% to -$0.0 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.0 (Q1 2026), -$0.0 (Q4 2025), and -$0.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 6.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Dec 31, 2014 | -0.02 |